Content about Corporate crime

April 17, 2014

Teva Pharmaceutical announced that its U.S. subsidiary has entered into a settlement with Pfizer related to Teva's generic version of Celebrex (celecoxib) 50-, 100-, 200- and 400-mg capsules in the United States.

JERUSALEM — Teva Pharmaceutical on Thursday announced that its U.S. subsidiary has entered into a settlement with Pfizer related to Teva's generic version of Celebrex (celecoxib) 50-, 100-, 200- and 400-mg capsules in the United States.

Under the terms of the settlement, Teva may launch its generic versions in December, 2014, or earlier under certain circumstances. Teva has received tentative approval from the Food and Drug Administration for all strengths and believes that it is first-to-file on at least the 100-, 200- and 400-mg capsules. 

April 11, 2014

Ian Read, chairman and CEO of Pfizer, was elected chairman of the Pharmaceutical Research and Manufacturers of America at the trade association’s annual meeting.

WASHINGTON — Ian Read, chairman and CEO of Pfizer, Inc, was elected chairman of the Pharmaceutical Research and Manufacturers of America Friday at the trade association’s annual meeting. Also elected were Kenneth Frazier, chairman, president and CEO of Merck, as chairman-elect of the PhRMA board of directors, and George Scangos, CEO of Biogen Idec, as board treasurer.

Read succeeds Robert Hugin, chairman and CEO of Celgene Corp., as PhRMA’s chairman.

March 18, 2014

Pfizer has sued Torrent Pharmaceuticals in an effort to protect its erectile-dysfunction drug Viagra (sildenafil citrate) from generic competition, according to a Bloomberg News report published Tuesday.

NEW YORK — Pfizer has sued Torrent Pharmaceuticals in an effort to protect its erectile-dysfunction drug Viagra (sildenafil citrate) from generic competition, according to a Bloomberg News report published Tuesday

Torrent has filed an aNDA with the Food and Drug Administration, challenging Pfizer's patent that expires on Oct. 22, 2019. 

March 3, 2014

Pfizer is recruiting for a 1,200-patient actual use study to measure whether or not patients can appropriately self-select treating high cholesterol with the statin Lipitor, the Wall Street Journal reported on Sunday.

NEW YORK — Pfizer is recruiting for a 1,200-patient actual use study to measure whether or not patients can appropriately self-select treating high cholesterol with the statin Lipitor, the Wall Street Journal reported on Sunday. 

The trial is recruiting patients through more than 35 pharmacies and is expected to be completed by year-end.  

January 24, 2014

Armada Health Care on Thursday added featured speaker Myrtle Potter to its card at the 2014 Specialty Pharmacy Summit and Expo to be held in Las Vegas May 5 to 9.

FLORHAM PARK, N.J. — Armada Health Care on Thursday added featured speaker Myrtle Potter to its card at the 2014 Specialty Pharmacy Summit and Expo to be held in Las Vegas May 5 to 9. The specialty pharmacy group also announced the addition of a pre-conference seminar/workshop to take place on May 5 and 6. 

Potter will join a speaker faculty of more than 50 other industry experts at this conference with a presentation titled, "Healthcare Leaders: How Will You Successfully Navigate the Healthcare Storm?". 

January 21, 2014

Greenstone, a U.S.-based generic pharmaceutical subsidiary of Pfizer, on Tuesday announced the introduction of Sirolimus to its generic pharmaceutical product line.

PEAPACK, N.J. — Greenstone, a U.S.-based generic pharmaceutical subsidiary of Pfizer, on Tuesday announced the introduction of Sirolimus to its generic pharmaceutical product line. The product is offered in dosage strengths of 0.5mg x 100. 

Greenstone’s Sirolimus product is the authorized generic of, and equivalent to, Pfizer's Rapamune (sirolimus). 

January 14, 2014

Three drug makers are looking into buying Pfizer's branded-generics drug business, according to published reports.

NEW YORK — Three drug makers are looking into buying Pfizer's branded-generics drug business, according to published reports.

Reuters reported that Actavis, Valeant Pharmaceuticals International and Mylan had expressed interest in buying Pfizer's business segment focused on generic drugs. However, Reuters reported that Pfizer was not yet ready to make a deal and was in the process of a potential separation of the generics unit.

December 2, 2013

Pfizer on Monday announced that a wholly-owned Polish subsidiary of Pfizer has acquired the rights to Polocard, a low-dose aspirin (acidum acetylsalicylicum), and the leading over-the-counter brand for heart attack prevention in Poland, from ZF Polpharma SA.

NEW YORK — Pfizer on Monday announced that a wholly-owned Polish subsidiary of Pfizer has acquired the rights to Polocard, a low-dose aspirin (acidum acetylsalicylicum), and the leading over-the-counter brand for heart attack prevention in Poland, from ZF Polpharma SA.

November 5, 2013

The Food and Drug Administration has approved a generic drug made by Mylan for treating overactive bladder, according to agency records.

SILVER SPRING, Md. — The Food and Drug Administration has approved a generic drug made by Mylan for treating overactive bladder, according to agency records.

The FDA approved Mylan's tolterodine tartrate extended-release capsules in the 2-mg and 4-mg strengths.

The drug is a generic version of Pfizer's Detrol LA. Detrol LA has annual sales of about $700 million, according to published reports.

 

September 10, 2013

What a difference a year will make. While sales of antacid tablets were down 1.3% to $2 billion for the 52 weeks ended July 14 across total U.S. multi-outlets, according to IRI, the entire category ought to have made a significant resurgence by this time next year.

What a difference a year will make. While sales of antacid tablets were down 1.3% to $2 billion for the 52 weeks ended July 14 across total U.S. multi-outlets, according to IRI, the entire category ought to have made a significant resurgence by this time next year.

September 4, 2013

A joint venture founded by GlaxoSmithKline and Pfizer focused on treatments for HIV has expanded its support of community organizations in the South.

RESEARCH TRIANGLE PARK, N.C. — A joint venture founded by GlaxoSmithKline and Pfizer focused on treatments for HIV has expanded its support of community organizations in the South.

July 3, 2013

Drug maker Impax Labs is hoping to become the first to market a generic version of a drug used to treat incontinence and overactive bladder, the company said Wednesday.

HAYWARD, Calif. — Drug maker Impax Labs is hoping to become the first to market a generic version of a drug used to treat incontinence and overactive bladder, the company said Wednesday.

June 17, 2013

Stephen Courtman, president of Health Mart, discusses what's new for Health Mart members at McKesson ideaShare this year and what's next for the independent pharmacy network.

DSN talks to Health Mart president Stephen Courtman about how Health Mart is helping its members stay competitive through new programs and services aimed at improving patient lives and growing profits.

DSN: What is new for Health Mart members at McKesson ideaShare this year?

February 19, 2013

The Food and Drug Administration has granted priority review to an experimental drug made by ViiV Healthcare for HIV, the company, a joint venture between British drug maker GlaxoSmithKline and American drug maker Pfizer, announced.

LONDON — The Food and Drug Administration has granted priority review to an experimental drug made by ViiV Healthcare for HIV, the company, a joint venture between British drug maker GlaxoSmithKline and American drug maker Pfizer, announced.

The FDA gave the designation to dolutegravir, designed for use in combination with other antiretrovirual drugs in adults and adolescents. The agency gives priority review to drugs that offer significant improvement compared with products already on the market.

December 3, 2012

Pfizer on Friday announced that it has completed the sale of its nutrition business to Nestlé for $11.9 billion in cash, following the conclusion of the required regulatory process in most markets.

NEW YORK — Pfizer on Friday announced that it has completed the sale of its nutrition business to Nestlé for $11.9 billion in cash, following the conclusion of the required regulatory process in most markets. In certain countries where completion will be delayed due to ongoing regulatory review, Pfizer will continue to operate the business on an interim basis.

October 22, 2012

Pfizer is buying the maker of an attention deficit hyperactivity disorder drug for almost $700 million, Pfizer said Monday.

NEW YORK — Pfizer is buying the maker of an attention deficit hyperactivity disorder drug for almost $700 million, Pfizer said Monday.

The drug maker announced that it would buy privately owned NextWave Pharmaceuticals, which makes the extended-release ADHD drug Quillivant XR (methylphenidate hydrochloride), which the Food and Drug Administration approved last month. The drug is expected to appear in pharmacies in January 2013.

October 16, 2012

Pfizer on Monday was awarded the National Community Pharmacists Association 2012 Corporate Recognition Award at NCPA's 114th Annual Convention and Trade Exposition, the association announced Monday.

 SAN DIEGO — Pfizer on Monday was awarded the National Community Pharmacists Association 2012 Corporate Recognition Award at NCPA's 114th Annual Convention and Trade Exposition, the association announced Monday. 

September 13, 2012

Pfizer has inked a deal with a Chinese drug maker to make branded-generic drugs for China and global markets, the companies said.

HANGZHOU, China — Pfizer has inked a deal with a Chinese drug maker to make branded-generic drugs for China and global markets, the companies said.

August 22, 2012

The Food and Drug Administration has postponed its decision whether or not to approve an experimental arthritis drug made by Pfizer, the drug maker said.

NEW YORK — The Food and Drug Administration has postponed its decision whether or not to approve an experimental arthritis drug made by Pfizer, the drug maker said.

Pfizer said the FDA had extended its action date for the drug tofacitinib by three months, to Nov. 21, because additional analyses of data that the company submitted constituted a "major amendment" to Pfizer's regulatory application and will require additional time to review.

August 17, 2012

Pfizer's general counsel Amy Schulman has assumed the reigns to Pfizer's consumer healthcare business, the Wall Street Journal reported earlier this week.

NEW YORK — Pfizer's general counsel Amy Schulman has assumed the reigns to Pfizer's consumer healthcare business, the Wall Street Journal reported earlier this week.

Schulman replaces Cavan Redmond, who was named the CEO of WebMD Health.

Pfizer Consumer Healthcare president Paul Sturman, who directly oversees the day-to-day operations of the consumer division, will now report to Schulman.

 

July 24, 2012

A district court ruled in favor of Pfizer and Northwestern University in a patent infringement case relating to Lyrica (pregabalin).

NEW YORK — A district court ruled in favor of Pfizer and Northwestern University in a patent infringement case relating to Lyrica (pregabalin).

July 24, 2012

An experimental drug under development by Pfizer and a unit of Johnson & Johnson does not appear effective in Alzheimer's disease patients who carry a certain genotype, according to results of a late-stage clinical trial announced by Pfizer on Tuesday.

NEW YORK — An experimental drug under development by Pfizer and a unit of Johnson & Johnson does not appear effective in Alzheimer's disease patients who carry a certain genotype, according to results of a late-stage clinical trial announced by Pfizer on Tuesday.

July 23, 2012

A drug made by Pfizer for treating pain disorders doesn't affect men's reproductive functions, according to a new post-approval clinical study.

NEW YORK — A drug made by Pfizer for treating pain disorders doesn't affect men's reproductive functions, according to a new post-approval clinical study.

The drug maker announced Monday the results of study A0081104 of Lyrica (pregabalin), which compared the drug with placebo in healthy males to assess its effects on sperm production. The phase-4 study was required by the Food and Drug Administration.

May 29, 2012

An experimental drug made by Pfizer for a rare and fatal neurodegenerative disease got a favorable vote from a Food and Drug Administration expert panel.

NEW YORK — An experimental drug made by Pfizer for a rare and fatal neurodegenerative disease got a favorable vote from a Food and Drug Administration expert panel.

The FDA's Peripheral and Central Nervous System Drugs Advisory Committee voted 13-4 that the drug tafamidis meglumine would provide certain clinical benefits to patients with transthyretin familial amyloid polyneuropathy, or TTR-FAP, a hereditary disease that affects about 8,000 people worldwide. The FDA is not required to follow the recommendations of FDA advisory committees, but usually does.

May 16, 2012

An experimental kidney cancer drug made by Pfizer didn't extend the time in which patients survived without their disease worsening when compared with a competing drug, according to results of a late-stage clinical trial released Wednesday.

NEW YORK — An experimental kidney cancer drug made by Pfizer didn't extend the time in which patients survived without their disease worsening when compared with a competing drug, according to results of a late-stage clinical trial released Wednesday.